Published in final edited form as:

Mol Cancer Res. 2019 July ; 17(7): 1450–1458. doi:10.1158/1541-7786.MCR-19-0002.

The PKR-like endoplasmic reticulum kinase promotes the dissemination of Myc-induced leukemic cells

Jun Gui¹, Kanstantsin V. Katlinski¹, Constantinos Koumenis², J. Alan Diehl³, and Serge Y. Fuchs^{1,*}

¹Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

²Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

³Department of Biochemistry, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA

Abstract

Hyperactive oncogenic Myc stimulates protein synthesis that induces the unfolded protein response, which requires the function of the eukaryotic translation initiation factor 2-alpha kinase 3, also known as protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). Activated PERK acts to limit mRNA translation, enable proper protein folding and restore the homeostasis in the endoplasmic reticulum. Given that Myc activation contributes to many types of lymphoid and myeloid human leukemias, we used a mouse model to examine the importance of PERK in development and progression of Myc-induced leukemias. We found that genetic ablation of *Perk* does not suppress the generation of the leukemic cells in the bone marrow. However, the cell-autonomous *Perk* deficiency restricts the dissemination of leukemic cells into peripheral blood, lymph nodes and vital peripheral organs. Whereas the loss of the IFNAR1 chain of type I interferon receptor stimulated leukemia, *Perk* ablation did not stabilize IFNAR1 suggesting that PERK stimulates the leukemic cells dissemination in an IFNAR1-independent manner. We discuss the rationale for using PERK inhibitors against Myc-driven leukemias.

Keywords

PERK; EIF2AK3; c-Myc; leukemia; interferon; IFNAR1; unfolded protein response

*Corresponding author: Serge Y. Fuchs, syfuchs@upenn.edu, tel. (215) 573-6949 fax (215) 746-2295.

Author contributions

J.G., C.K., J.A.D. and S.Y.F. designed the research. J.G., K.V.K., and S.Y.F. performed the experiments and analyzed data. J.G. and S.Y.F. wrote the paper with help of all authors.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Introduction

Eukaryotic translation initiation factor 2- α kinase 3, also known as protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is a critical regulator of the unfolded protein response, which includes several signaling pathways that act to restore and maintain the homeostasis of the endoplasmic reticulum (1). Protein and lipid kinase activities of PERK play a central role in determining the viability of cells undergoing the unfolded protein response (2). Whereas earlier studies clearly suggested that PERK functions as a pro-apoptotic regulator, more recently it has been demonstrated that, in the context of oncogene- and tumor microenvironment-induced stresses associated with tumor growth, activation of PERK might be required for cell survival and tumor progression (2, 3). These cell viability-supporting roles of PERK are supported by its ability to activate autophagy (3, 4) and induce the pro-survival miRNAs (5–7).

In addition, PERK plays a central role in suppressing the pro-apoptotic effects mediated by type I interferons (IFN) (8–11). The latter effect is conferred by the endoplasmic reticulum stress-induced activation of PERK, which, in turn, stimulates the p38 stress activating kinase and, together with casein kinase 1 α , phosphorylates the IFNAR1 chain of IFN receptor (8, 12–18). This phosphorylation enables the recruitment of the β -TrCP E3 ubiquitin ligase, which facilitates ubiquitination, endocytosis and degradation of IFNAR1 leading to attenuation of IFN signaling and IFN-induced inhibition of cell proliferation and viability (19–21).

Accordingly, PERK plays a complex role function in tumorigenesis (2, 22, 23). PERK is induced during tumor development and progression in response to the stress stimuli originating from activation oncogenes (such as c-Myc) or/and deficit of glucose and oxygen in the tumor microenvironment (1). Whereas tempered PERK activities (due to hypomorphic mutants or haploinsufficiency) may promote initiation of melanomas (24), the complete ablation or inhibition of PERK is incompatible with solid tumor growth (4, 24–27). These findings prompted academic and industrial efforts to develop potent and selective inhibitors of PERK (28).

Hyperactive Myc oncogenes were shown to promote robust protein synthesis that can outmatch the ability of the endoplasmic reticulum to quickly fold these proteins or degrade unfolded protein leading to the induction of the unfolded protein response and activation of PERK (4, 29). Importantly, activated PERK contributes to tumor progression in lymphomas and mammary adenocarcinomas (4, 6, 25). Whereas these studies clearly indicate the importance of PERK in development and progression of solid tumors, little is known about the role of PERK in leukemias in general and in the context of Myc-driven leukemias in particular. Myc is overexpressed in human acute and chronic myeloid leukemias (30–32). In addition, Myc translocations, rearrangements, amplification or overexpression are also found in acute lymphoblastic leukemias (33–35). Here we used a mouse model that involved expression of c-Myc in transplanted bone marrow cells combined with conditional and inducible cell-autonomous genetic ablation of *Perk* to determine the role of PERK in Myc-induced leukemia. We found that PERK plays an important role in supporting the dissemination of leukemic cells.

Materials and Methods

Plasmids and Retroviruses

The plasmids MSCV-cMyc-IRES-GFP (MIGR1-cMyc)/vector control (MIGR1-Ctrl), and the packaging vectors (PCGP and PHIT) were kindly provided by Dr. Warren Pear (University of Pennsylvania, Philadelphia, USA). These plasmids were co-transfected into 293T cells (ATCC® CRL-3216™) by using the Calcium Phosphate Transfection Kit according to the manufactures' instructions (Invitrogen). Retroviral supernatant was harvested 24 and 48 hours after transfection, filtered and stored at -80°C . The titer of the infectious virus was determined by flow cytometry using NIH3T3 cells (ATCC® CRL-1658™) infected with serial dilution of virus in the presence of 8 $\mu\text{g/ml}$ Polybrene (Sigma). Both the 293T and NIH3T3 cells were purchased from ATCC and maintained in Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% Fetal Bovine Serum (HyClone) and 100 U/ml Penicillin-Streptomycin (Gibco). Cell lines were regularly tested for mycoplasma.

Animals

All experiments with animals were carried out under the protocol 803995 approved by the Institutional Animal Care and Use Committee (IACUC) of The University of Pennsylvania. Mice were maintained in a specific pathogen-free facility in accordance with American Association for Laboratory Animal Science guidelines. C57BL/6 *Ifnar1*^{-/-} mice were generously provided by Dr. Susan Weiss (University of Pennsylvania, Philadelphia, USA). *Ubc9-CreERT2* mice (gift from E. Brown, University of Pennsylvania) were crossed with *Perk*^{fl/fl} mice (kindly provided by J. Alan Diehl, Medical University of South Carolina) to generate *Ubc9-CreERT2*^{+/-}; *Perk*^{fl/fl} littermates. The littermates were all C57BL/6 and 129 mix background. Genotyping of mice using tail DNA was performed by PCR as previously described (11).

Bone Marrow Transplantation

Bone marrow cells were collected from 6 to 8 week-old WT (*Ifnar1*^{+/+}), *Ifnar1*^{-/-}, *Perk*^{fl/fl} *Ubc9-CreERT2*⁻ or *Perk*^{fl/fl} *Ubc9-CreERT2*⁺ mice 4 days after i.p. administration of 5-FU (150mg/kg) and retrovirally transduced *ex vivo* in the presence of IL3 (6 ng/ml), IL-6 (5 ng/ml), SCF (100 ng/ml) and polybrene (4 $\mu\text{g/ml}$) twice. Retroviral supernatants with equal titers were used to produce similar transduction efficiencies. The c-Myc/Ctrl transduced bone marrow cells were mixed with non-infected bone marrow cells isolated from WT mice in the ratio of 9:1, with a total of 1×10^6 cells retroorbitally injected into each lethally irradiated (915 rad) C57BL/6 recipient mouse. Chimeric mice were maintained on antibiotics for 2 weeks.

Tamoxifen treatment

To induce *Perk* deletion in the donor cells, one month after bone marrow transplantation, tamoxifen (Sigma) was dissolved in maize oil (Sigma) and given once daily via oral gavage for 5 consecutive days at a dose of 0.2 mg/g of body weight/day. Time after tamoxifen treatment was determined after the last treatment.

Analysis of mice

Mice were monitored for disease development three times per week by palpation and observation. Peripheral blood was obtained by either cutting tail or cardiac puncture after CO₂ euthanization. Blood smear Wright Giemsa staining and blood cell counts were performed in the Department of Pathology, School of Veterinary Medicine in University of Pennsylvania. Mononuclear-cell suspensions of spleen, bone marrow, or lymph nodes were made by passing tissue through nylon mesh cell strainers. Tissues from the mice were stored in a 4% PFA-PBS. Formalin-fixed tissue slides were stained with hematoxylin and eosin (H&E) and were imaged using an Olympus BX40 F4 microscope (Olympus Optical, Tokyo, Japan). Pictures were taken with an Olympus DP70 digital camera using DPController software. The quantification of the area of lesions in the tissues was performed by Image J.

Flow cytometric analysis

Single-cell suspensions prepared from peripheral blood, bone marrow, spleen and lymph node were re-suspended in FACS buffer (PBS plus 1% BSA) and blocked with anti-mouse CD16/32 antibodies for 15 mins prior to staining with specific antibodies. Antibody against cell surface IFNAR1 (anti-IFNAR1-PE) was purchased from Biolegend. Samples were mixed with DAPI (1 ug/ml) and acquired on LSRFortessa flow cytometer (BD Biosciences), and data were analyzed with FlowJo software (Tree Star).

Statistical analysis

Data were expressed as mean $\pm$ SEM. Statistical analysis was performed using GraphPad Prism 6 software (GraphPad Prism Software Inc.). Unpaired Student t test was used for the comparison between two groups. One-way ANOVA or two-way ANOVA were used for the multiple comparisons. Differences were considered significant at $p < 0.05$. All described results are representative of at least 3 independent experiments.

Results

In solid tumors, function of PERK was shown to be important for survival of cells harboring activated Myc (3–5, 36). Previous studies that utilized the retroviral-mediated expression of diverse Myc oncogenes in murine bone marrow cells followed by transplantation of these cells into lethally irradiated host described development of acute leukemia in these models (37–41). We have used this approach to determine the importance of PERK in Myc-induced leukemia.

To this end, bone marrow progenitors from 5-fluorouracil-treated *Perk^{fl/fl} Ubc9-CreER⁻* or *Perk^{fl/fl} Ubc9-CreER⁺* donor mice were transduced with retroviruses for expressing c-Myc and GFP (or GFP alone), mixed with bone marrow cells from naïve wild type mice (to ensure normal hematopoiesis) and transplanted into irradiated wild type recipients. This approach was chosen to first ensure proper reconstitution of bone marrow in recipients and then enable us to follow the fate of GFP⁺ cells harboring or not Myc (Figure 1A). Indeed, thirty days after transplantation, the recipient animals did not display any visible signs of illness and their peripheral blood analysis showed normal parameters including numbers of white and red blood cells and hematocrit (Figure 1B). Interestingly, at this time point where

total leukocytes numbers have not yet changed, a statistically significant increase in percent of GFP-positive cells was already observed in mice that receive cells transduced by c-Myc (Figures 1C–D).

To determine the importance of PERK in Myc-induced proliferation of hematopoietic cells, we have further examined the numbers of GFP⁺ cells in different compartments upon *Perk* genetic ablation, which was induced by treatment of recipient mice with tamoxifen (Figure 1A). Analysis of GFP-positive bone marrow cells in recipient mice at 40–60 days after transplantation revealed that *Perk* was successfully deleted upon tamoxifen treatment (Figure 2A). *Perk* ablation did not affect either the levels of c-Myc expression (Figure 2A) or the percentage of GFP⁺ cells in bone marrow (Figure 2B). The latter result is consistent with a recent report that *Perk* is dispensable for the maintenance of normal hematopoietic stem and progenitor cells (42). Intriguingly, we observed a modest (but not significant) trend towards a decrease in GFP⁺ cells in the spleen (Figure 2C). Importantly, deletion of *Perk* significantly decreased the numbers of GFP-positive cells in the lymph nodes and peripheral blood (Figure 2D–E) suggesting that *Perk* might contribute to dissemination of GFP⁺ c-Myc-expressing cells.

Careful examination revealed the signs of Myc-induced leukemia in recipient mice observed on days 40–60 after bone marrow transplantation as differences between mice that received bone marrow transduced with c-Myc and control mice harboring WT bone marrow transduced with GFP only. The Myc-induced leukemia manifested itself as leukocytosis, splenomegaly and lymphadenopathy (Figure 3A–E) as well as leukemic lesions found in the liver, lungs and kidneys (Figure 3F–G). Importantly, ablation of *Perk* resulted in significant decrease in the number of peripheral blood leukocytes (Figure 3A–B), size of the lymph nodes (Figure 3C, E) and the number of leukemic lesions (Figure 3F–G). Taken together with a trend for attenuated splenomegaly (Figure 3C–D), these results further suggest that PERK functions to support the dissemination of Myc-induced leukemic malignant cells.

Previous reports demonstrated that activated PERK acts to downregulate the IFNAR1 chain of type I interferon receptor and to suppress type I interferon pathway (8–11). As ablation of *Perk* stabilized IFNAR1 in melanoma cells, normal fibroblasts and pancreatic cells (8, 11), and stabilization of IFNAR1 in the host was shown to limit dissemination of transplanted syngeneic acute leukemia cells (43) we next sought to determine whether the loss of IFNAR1 contributes to the phenotypes of Myc-induced leukemia. To this end, we used donor bone marrow cells from *Ifnar1*^{+/+} (WT) or *Ifnar1*^{-/-} mice for their transduction with c-Myc/GFP and transplantation into irradiated WT hosts (Figure 4A).

Mice that received c-Myc/GFP-expressing cells lacking IFNAR1 displayed a greater number of GFP⁺ leukemic cells in their blood (Figures 4B–C) indicating that the loss of type I IFN signaling may promote the leukemogenic effect of c-Myc. Indeed, animals that received IFNAR1-deficient bone marrow cells displayed a greater leukocytosis (Figure 4D–E) and splenomegaly (Figure 4F–G) further supporting the anti-tumorigenic role of IFNAR1 in pathogenesis of Myc-driven acute leukemia.

However, analysis of IFNAR1 on the surface of *Perk*-null or *Perk*-competent leukemic cells isolated from bone marrow, spleen or lymph nodes showed that ablation of *Perk* did not affect IFNAR1 levels (Figure 5A–F). These results are consistent with previous reports that PERK status does not affect IFNAR1 levels on normal hematopoietic stem and progenitor cells (42) suggesting that there are redundant pathways in hematopoietic cells that affect IFNAR1 status and type I IFN pathway. These data also indirectly suggest that anti-leukemogenic effects of *Perk* ablation might be mediated by pathways that are not dependent on IFNAR1.

Discussion

Previous reports that demonstrate the importance of PERK in development and progression of solid tumors driven by Myc oncogene (reviewed in (2, 3)) prompted us to examine the roles of PERK in Myc-induced leukemia. Here we show that ablation of *Perk* in Myc-expressing leukemic cells does not affect their numbers (Figures 1–2). These data suggest that PERK is dispensable for the maintenance of proliferation or/and viability of hematopoietic cells harboring c-Myc. Intriguingly, it has been previously reported that ablation of *Perk* does not affect the fate and proliferating potential of normal hematopoietic stem cells and progenitors (42) indicating that activities of additional regulators may render PERK function redundant for these biological processes.

However, we observed that genetic ablation of PERK impedes the ability of Myc-expressing cells to disseminate to peripheral blood and form lesions in peripheral organs including lymph nodes, spleen, lung, liver and kidney (Figure 3). These results indicate that PERK functions to support the dissemination of the leukemic cells and, accordingly, might play an important role in progression of Myc-driven leukemias. Thus, it can be argued that pharmacologic inhibitors of PERK proposed to be used against solid tumors (11, 24) might not be very efficient in helping to eradicate the Myc-induced leukemias but could be useful in slowing down the progression of the disease.

The mechanisms by which PERK expression in the cells harboring activated Myc supports the dissemination of these cells remain to be elucidated. One of potential mechanisms we considered is the alteration of IFN signaling, which is known to suppress the metastatic processes and contribute to expression of numerous chemokines and their receptors that could guide leukemic cells dissemination (44, 45). Indeed, previous reports suggested that PERK signals towards accelerated ubiquitination and degradation of the IFNAR1 chain of IFN receptor (9). Furthermore, our current data show that ablation of IFNAR1 indeed promoted the development and progression of the Myc-driven leukemia (Figure 4). However, no perturbation of IFNAR1 levels was observed upon *Perk* ablation (Figure 5). It is plausible that, in the context of Myc activation, stimulating effects of PERK on ubiquitination of IFNAR1 are counteracted by IFNAR1 de-ubiquitination, which is facilitated by the BRISC de-ubiquitination complex recruited to IFNAR1 via serine hydroxymethyltransferase-2 (46). Importantly, serine hydroxymethyltransferase-2 is known as a canonical Myc-induced protein (47). Thus, induction of serine hydroxymethyltransferase-2 and ensuing de-ubiquitination of IFNAR1 may offset stimulation of IFNAR1 ubiquitination driven by PERK.

Furthermore, although our results may be interpreted in a way that PERK is redundant in the bone marrow cells for the regulation of IFNAR1 stability and signaling, we cannot rule out that PERK status still affects the IFN pathway through acting on other mediators of IFN signaling (such as IFNAR2, Janus kinases or STAT proteins). Future studies will test this possibility as well as reveal the mechanisms by which PERK contributes to dissemination of leukemic cells and evaluate the usefulness of PERK inhibitors for the treatment of Myc-associated leukemias.

Acknowledgments

We thank Dr. Warren Pear for the kind gift of reagents and the members of Fuchs, Koumenis and Diehl lab for discussion and valuable suggestions. This work was supported by the NIH/NCI PO1 CA165997 grant (to C.K., J.A.D., and S.Y.F.), and RO1 grants CA092900 and CA216936 (to S.Y.F.), as well as by additional support from T32 CA009140 (to K.V.K.).

References

1. Diehl JA, Fuchs SY, Koumenis C. The cell biology of the unfolded protein response. *Gastroenterology*. 2011;141(1):38–41, e1–2. doi: 10.1053/j.gastro.2011.05.018. [PubMed: 21620842]
2. Bu Y, Diehl JA. PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. *J Cell Physiol*. 2016;231(10):2088–96. doi: 10.1002/jcp.25336. [PubMed: 26864318]
3. Dey S, Tameire F, Koumenis C. PERK-ing up autophagy during MYC-induced tumorigenesis. *Autophagy*. 2013;9(4):612–4. doi: 10.4161/auto.23486. [PubMed: 23328692]
4. Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, Koumenis C. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. *J Clin Invest*. 2012;122(12):4621–34. doi: 10.1172/JCI62973. [PubMed: 23143306]
5. Bu Y, Yoshida A, Chitnis N, Altman BJ, Tameire F, Oran A, Gennaro V, Armeson KE, McMahon SB, Wertheim GB, Dang CV, Ruggero D, Koumenis C, Fuchs SY, Diehl JA. A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. *Nat Cell Biol*. 2018;20(1):104–15. doi: 10.1038/s41556-017-0006-y. [PubMed: 29230015]
6. Chitnis NS, Pytel D, Bobrovnikova-Marjon E, Pant D, Zheng H, Maas NL, Frederick B, Kushner JA, Chodosh LA, Koumenis C, Fuchs SY, Diehl JA. miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner. *Mol Cell*. 2012;48(3):353–64. doi: 10.1016/j.molcel.2012.08.025. [PubMed: 23022383]
7. Xu Z, Bu Y, Chitnis N, Koumenis C, Fuchs SY, Diehl JA. miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis. *Nat Commun*. 2016;7:11422. doi: 10.1038/ncomms11422. [PubMed: 27173017]
8. Bhattacharya S, HuangFu WC, Dong G, Qian J, Baker DP, Karar J, Koumenis C, Diehl JA, Fuchs SY. Anti-tumorigenic effects of Type I interferon are subdued by integrated stress responses. *Oncogene*. 2013;32(36):4214–21. doi: 10.1038/onc.2012.439. [PubMed: 23045272]
9. Fuchs SY. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research*. 2013;33(4):211–25. doi: 10.1089/jir.2012.0117.
10. Liu J, HuangFu WC, Kumar KG, Qian J, Casey JP, Hamanaka RB, Grigoriadou C, Aldabe R, Diehl JA, Fuchs SY. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. *Cell Host Microbe*. 2009;5(1):72–83. doi: 10.1016/j.chom.2008.11.008. [PubMed: 19154989]
11. Yu Q, Zhao B, Gui J, Katlinski KV, Brice A, Gao Y, Li C, Kushner JA, Koumenis C, Diehl JA, Fuchs SY. Type I interferons mediate pancreatic toxicities of PERK inhibition. *Proc Natl Acad Sci U S A*. 2015;112(50):15420–5. doi: 10.1073/pnas.1516362112. [PubMed: 26627716]

12. Bhattacharya S, HuangFu WC, Liu J, Veeranki S, Baker DP, Koumenis C, Diehl JA, Fuchs SY. Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. *J Biol Chem*. 2010;285(4):2318–25. doi: 10.1074/jbc.M109.071498. [PubMed: 19948722]
13. Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Gironde M, Rui H, May MJ, Avadhani NG, Rustgi AK, Fuchs SY. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. *EMBO Mol Med*. 2014;6(3):384–97. doi: 10.1002/emmm.201303236. [PubMed: 24480543]
14. Bhattacharya S, Qian J, Tzimas C, Baker DP, Koumenis C, Diehl JA, Fuchs SY. Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. *J Biol Chem*. 2011;286(25):22069–76. doi: 10.1074/jbc.M111.238766. [PubMed: 21540188]
15. Liu J, Carvalho LP, Bhattacharya S, Carbone CJ, Kumar KG, Leu NA, Yau PM, Donald RG, Weiss MJ, Baker DP, McLaughlin KJ, Scott P, Fuchs SY. Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. *Mol Cell Biol*. 2009;29(24):6401–12. doi: 10.1128/MCB.00478-09. [PubMed: 19805514]
16. Liu J, Plotnikov A, Banerjee A, Suresh Kumar KG, Ragimbeau J, Marijanovic Z, Baker DP, Pellegrini S, Fuchs SY. Ligand-independent pathway that controls stability of interferon alpha receptor. *Biochem Biophys Res Commun*. 2008;367(2):388–93. doi: 10.1016/j.bbrc.2007.12.137. [PubMed: 18166147]
17. Huangfu WC, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY. Inflammatory signaling compromises cell responses to interferon alpha. *Oncogene*. 2012;31(2):161–72. doi: 10.1038/onc.2011.221. [PubMed: 21666722]
18. Qian J, Zheng H, Huangfu WC, Liu J, Carbone CJ, Leu NA, Baker DP, Fuchs SY. Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. *PLoS Pathog*. 2011;7(6):e1002065. doi: 10.1371/journal.ppat.1002065. [PubMed: 21695243]
19. Kumar KG, Krolewski JJ, Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. *J Biol Chem*. 2004;279(45):46614–20. [PubMed: 15337770]
20. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. *Embo J*. 2003;22(20):5480–90. [PubMed: 14532120]
21. Katlinskaya YV, Katlinski KV, Lasri A, Li N, Beiting DP, Durham AC, Yang T, Pikarsky E, Lengner CJ, Johnson FB, Ben-Neriah Y, Fuchs SY. Type I Interferons Control Proliferation and Function of the Intestinal Epithelium. *Mol Cell Biol*. 2016;36(7):1124–35. doi: 10.1128/MCB.00988-15. [PubMed: 26811327]
22. Chitnis N, Pytel D, Diehl JA. UPR-inducible miRNAs contribute to stressful situations. *Trends Biochem Sci*. 2013;38(9):447–52. doi: 10.1016/j.tibs.2013.06.012. [PubMed: 23906563]
23. Pytel D, Majsterek I, Diehl JA. Tumor progression and the different faces of the PERK kinase. *Oncogene*. 2016;35(10):1207–15. doi: 10.1038/onc.2015.178. [PubMed: 26028033]
24. Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. *PLoS Genet*. 2016;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. [PubMed: 27977682]
25. Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, Cavener D, Diehl JA. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. *Oncogene*. 2010;29(27):3881–95. doi: 10.1038/onc.2010.153. [PubMed: 20453876]
26. Lehman SL, Ryeom S, Koumenis C. Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma. *Sci Rep*. 2015;5:11781. doi: 10.1038/srep11781. [PubMed: 26123823]
27. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress-induced autophagy overcomes BRAF inhibitor

- resistance in melanoma. *J Clin Invest*. 2014;124(3):1406–17. doi: 10.1172/JCI70454. [PubMed: 24569374]
28. Rozpedek W, Pytel D, Dziki L, Nowak A, Dziki A, Diehl JA, Majsterek I. Inhibition of PERK-dependent pro-adaptive signaling pathway as a promising approach for cancer treatment. *Pol Przegl Chir*. 2017;89(3):7–10.
 29. Nagy P, Varga A, Pircs K, Hegedus K, Juhasz G. Myc-driven overgrowth requires unfolded protein response-mediated induction of autophagy and antioxidant responses in *Drosophila melanogaster*. *PLoS Genet*. 2013;9(8):e1003664. doi: 10.1371/journal.pgen.1003664. [PubMed: 23950728]
 30. Court EL, Smith MA, Avent ND, Hancock JT, Morgan LM, Gray AG, Smith JG. DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines. *Leuk Res*. 2004;28(7):743–53. doi: 10.1016/j.leukres.2003.11.011. [PubMed: 15158096]
 31. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Roskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. *Leukemia*. 2007;21(3):494–504. doi: 10.1038/sj.leu.2404549. [PubMed: 17252012]
 32. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. *Oncogene*. 2003;22(25):3952–63. doi: 10.1038/sj.onc.1206620. [PubMed: 12813469]
 33. Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd K, Cleveland JL, Grosveld GC. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. *Mol Cell Biol*. 2005;25(6):2395–405. doi: 10.1128/MCB.25.6.2395-2405.2005. [PubMed: 15743832]
 34. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. *Cancer*. 2010;116(5):1165–76. doi: 10.1002/cncr.24862. [PubMed: 20101737]
 35. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. *Semin Cancer Biol*. 2006;16(4):318–30. doi: 10.1016/j.semcancer.2006.07.015. [PubMed: 16934487]
 36. Tameire F, Verginadis II, Koumenis C. Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy. *Semin Cancer Biol*. 2015;33:3–15. doi: 10.1016/j.semcancer.2015.04.002. [PubMed: 25920797]
 37. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. *Oncogene*. 2009;28(9):1274–9. doi: 10.1038/onc.2008.466. [PubMed: 19137012]
 38. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. *Genes Cancer*. 2010;1(6):605–16. doi: 10.1177/1947601910377495. [PubMed: 21779460]
 39. Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. *Cancer Res*. 2007;67(22):10677–85. doi: 10.1158/0008-5472.CAN-07-1118. [PubMed: 18006809]
 40. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. *Blood*. 2005;106(7):2452–61. doi: 10.1182/blood-2005-02-0734. [PubMed: 15972450]
 41. Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. *Blood*. 2003;101(5):1950–5. doi: 10.1182/blood-2002-06-1797. [PubMed: 12406913]
 42. Gui J, Zhao B, Lyu K, Tong W, Fuchs SY. Downregulation of the IFNAR1 chain of type 1 interferon receptor contributes to the maintenance of the haematopoietic stem cells. *Cancer Biol Ther*. 2017;18(7):534–43. doi: 10.1080/15384047.2017.1345395. [PubMed: 28678581]
 43. Zhao B, Bhattacharya S, Yu Q, Fuchs SY. Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. *Leuk Lymphoma*. 2018;59(1):171–7. doi: 10.1080/10428194.2017.1319053. [PubMed: 28503979]
 44. Ortiz A, Fuchs SY. Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. *Cytokine*. 2017;89:4–11. doi: 10.1016/j.cyto.2016.01.010. [PubMed: 26822709]

45. Ruvolo PP. Galectins as regulators of cell survival in the leukemia niche. *Adv Biol Regul.* 2018. doi: 10.1016/j.jbior.2018.09.003.
46. Zheng H, Gupta V, Patterson-Fortin J, Bhattacharya S, Katlinski K, Wu J, Varghese B, Carbone CJ, Aressy B, Fuchs SY, Greenberg RA. A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. *Cell Rep.* 2013;5(1):180–93. doi: 10.1016/j.celrep.2013.08.025. [PubMed: 24075985]
47. Nikiforov MA, Chandriani S, O’Connell B, Petrenko O, Kotenko I, Beavis A, Sedivy JM, Cole MD. A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. *Mol Cell Biol.* 2002;22(16):5793–800. [PubMed: 12138190]

Implications:

The role of PERK in dissemination of Myc-induced leukemic cells demonstrated in this study argues for the use of PERK inhibitors against leukemia progression.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

A. Schematic illustration for the experiment design. Bone marrow cells were harvested from 5-FU injected donors (*Perk^{fl/fl}Ubc9-CreERT2⁺* and *Perk^{fl/fl}Ubc9-CreERT2⁻*) and transduced with c-Myc-GFP or control (GFP alone) retrovirus. The c-Myc/Ctrl transduced bone marrow cells were mixed with non-infected bone marrow cells isolated from WT mice in the ratio of 9:1, with a total of 1×10^6 cells retroorbitally injected into each lethally irradiated recipient mouse. Thirty days after bone marrow transplantation, mice were orally gavaged with tamoxifen (TAM) for 5 days to ablate *Perk* gene. WT mice that were transplanted with

control retrovirus transduced bone marrow cells isolated from WT (*Perk^{+/+}*) mice set as a control.

B. Blood cell counts in the peripheral blood of mice at day 30 after bone marrow transplantation, but before TAM treatment. WBC, white blood cells; RBC, red blood cells; HCT, hematocrit. Data shown as means $\pm$ SEM (n=3–4). NS, No significance.

C. Representative FACS analysis of percentage of GFP⁺ cells in the peripheral blood of mice at day 30 after bone marrow transplantation, but before TAM treatment.

D. Quantification of the percentage of GFP⁺ cells as described in C. Data shown as means $\pm$ SEM (n=3–4). **, $P<0.01$; NS, No significance.

Figure 2.

A. Representative western blot analysis of PERK and c-Myc expression in the bone marrow cells isolated from the recipient mice (reconstituted with indicated genotype bone marrow cells transduced with c-Myc or control (ctrl) retroviruses) after TAM treatment. Independent experiments were done three times with similar results.

B. Representative FACS analysis (left) and the quantification (right) of GFP⁺ cells in the bone marrow from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus after TAM treatment. Data shown as means $\pm$ SEM (n=3). NS, No significance.

C. Representative FACS analysis (left) and the quantification (right) of GFP⁺ cells in the spleen from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus after TAM treatment. Data shown as means±SEM (n=3). NS, No significance.

D. Representative FACS analysis (left) and the quantification (right) of GFP⁺ cells in the lymph node from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus after TAM treatment. Data shown as means±SEM (n=3). *, $P<0.05$.

E. Representative FACS analysis (left) and the quantification (right) of GFP⁺ cells in the peripheral blood from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus after TAM treatment. Data shown as means±SEM (n=3). *, $P<0.05$.

Figure 3.

A. Wright-Giemsa-stained peripheral blood smear from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus. Scale bar: 50 μm

B. White blood cell counts in the peripheral blood of the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus. Data shown as means ± SEM (n=3-6). *, P < 0.05.

C. Representative photographs of spleens, and lymph nodes derived from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus.

D. The quantification of spleen weight of the indicated mice as shown in C. Data shown as means ± SEM (n=3-8). *, P < 0.05. NS, No significance.

E. The quantification of lymph node size of the indicated mice as shown in C. Data shown as means ± SEM (n=4-8). **, P < 0.01. ***, P < 0.001.

F. Histology analysis of liver, lung and kidney of the indicated tumor-burdened mice with one representative field shown in each group. Scale bar: 100 μ m

G. Quantification of leukemic lesions in the tissues as shown in F. Data shown as means $\pm$ SEM (n=3). *, $P<0.05$; ***, $P<0.001$; N.D., not detected.

Figure 4.

A. Schematic illustration for the experiment design. Bone marrow cells were harvested from 5-FU injected donors (*Ifnar1*^{+/+} and *Ifnar1*^{-/-}) and transduced with c-Myc-GFP retrovirus. The c-Myc/Ctrl transduced bone marrow cells were mixed with non-infected bone marrow cells isolated from WT mice in the ratio of 9:1, with a total of 1×10^6 cells retroorbitally injected into each lethally irradiated recipient mouse. WT mice that were transplanted with control retrovirus transduced bone marrow cells isolated from WT mice set as a control.

B. Representative FACS analysis of percentage of GFP⁺ cells in the peripheral blood of the mice reconstituted with c-Myc transduced WT (c-Myc-*Ifnar1*^{+/+}) or IFNAR1 knock out (c-Myc-*Ifnar1*^{-/-}) bone marrow cells around 30 days after bone marrow transplantation.

C. Quantification of the percentage of GFP⁺ cells in the peripheral blood as described in B. Data shown as means±SEM (n=3). *, *P*<0.05.

D. Wright–Giemsa-stained peripheral blood smear from the indicated mice around 30 days after bone marrow transplantation. Scale bar: 50 μm

E. White blood cell counts in the peripheral blood of the indicated mice. Data were shown as means±SEM (n=3–6). **, *P*<0.01.

F. Representative photographs of spleens derived from the indicated mice.

G. Quantification of the spleen weight of the indicated mice as shown in F. Data shown as means±SEM (n=3–5). *, *P*<0.05; **, *P*<0.01.

Figure 5.

A. Representative FACS analysis of surface IFNAR1 level in the GFP positive bone marrow cells from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus.

B. Quantification of IFNAR1 level as described in A. Data shown as means±SEM (n=3). NS, no significance.

C. Representative FACS analysis of surface IFNAR1 level in the GFP positive splenocytes from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus.

D. Quantification of IFNAR1 level as described in C. Data shown as means±SEM (n=3). NS, no significance.

E. Representative FACS analysis of surface IFNAR1 level in the GFP positive lymph node cells from the mice reconstituted with the indicated genotype bone marrow cells transduced with c-Myc retrovirus.

F. Quantification of IFNAR1 level as described in E. Data shown as means $\pm$ SEM (n=3). NS, no significance.